Compare URG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URG | BNTC |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.7M | 396.3M |
| IPO Year | 2006 | 2020 |
| Metric | URG | BNTC |
|---|---|---|
| Price | $1.11 | $9.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $2.57 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 5.3M | 126.0K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,207,000.00 | N/A |
| Revenue This Year | $200.42 | N/A |
| Revenue Next Year | $98.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $9.26 |
| 52 Week High | $2.35 | $16.76 |
| Indicator | URG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 30.39 |
| Support Level | N/A | N/A |
| Resistance Level | $1.46 | $13.49 |
| Average True Range (ATR) | 0.05 | 0.73 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 6.90 | 12.77 |
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.